Pfizer Inc. (PFE)
NYSE: PFE · IEX Real-Time Price · USD
30.77
+1.01 (3.39%)
At close: Jul 26, 2024, 4:01 PM
30.69
-0.08 (-0.26%)
After-hours: Jul 26, 2024, 7:59 PM EDT
Pfizer Employees
Pfizer had 88,000 employees as of December 31, 2023. The number of employees increased by 5,000 or 6.02% compared to the previous year.
Employees
88,000
Change (1Y)
5,000
Growth (1Y)
6.02%
Revenue / Employee
$626,068
Profits / Employee
-$3,511
Market Cap
174.36B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 88,000 | 5,000 | 6.02% |
Dec 31, 2022 | 83,000 | 4,000 | 5.06% |
Dec 31, 2021 | 79,000 | 500 | 0.64% |
Dec 31, 2020 | 78,500 | -9,800 | -11.10% |
Dec 31, 2019 | 88,300 | -4,100 | -4.44% |
Dec 31, 2018 | 92,400 | 2,200 | 2.44% |
Dec 31, 2017 | 90,200 | -6,300 | -6.53% |
Dec 31, 2016 | 96,500 | -1,400 | -1.43% |
Dec 31, 2015 | 97,900 | 19,600 | 25.03% |
Dec 31, 2014 | 78,300 | 600 | 0.77% |
Dec 31, 2013 | 77,700 | -13,800 | -15.08% |
Dec 31, 2012 | 91,500 | -12,200 | -11.76% |
Dec 31, 2011 | 103,700 | -6,900 | -6.24% |
Dec 31, 2010 | 110,600 | -5,900 | -5.06% |
Dec 31, 2009 | 116,500 | 34,700 | 42.42% |
Dec 31, 2008 | 81,800 | -4,800 | -5.54% |
Dec 31, 2007 | 86,600 | -11,400 | -11.63% |
Dec 31, 2006 | 98,000 | -8,000 | -7.55% |
Dec 31, 2005 | 106,000 | -9,000 | -7.83% |
Dec 31, 2004 | 115,000 | -7,000 | -5.74% |
Dec 31, 2003 | 122,000 | 24,000 | 24.49% |
Dec 31, 2002 | 98,000 | 8,000 | 8.89% |
Dec 31, 2001 | 90,000 | 0 | - |
Dec 31, 2000 | 90,000 | 39,100 | 76.82% |
Dec 31, 1999 | 50,900 | 4,500 | 9.70% |
Dec 31, 1998 | 46,400 | -2,800 | -5.69% |
Dec 31, 1997 | 49,200 | 2,700 | 5.81% |
Dec 31, 1996 | 46,500 | 2,700 | 6.16% |
Dec 31, 1995 | 43,800 | 3,000 | 7.35% |
Dec 31, 1994 | 40,800 | 300 | 0.74% |
Dec 31, 1993 | 40,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
Elevance Health | 104,900 |
Sanofi | 86,088 |
Novartis AG | 76,057 |
Danaher | 63,000 |
Amgen | 26,700 |
Stryker | 26,700 |
PFE News
- 10 hours ago - Will Pfizer Stock Post A Downbeat Q2? - Forbes
- 1 day ago - European Commission Approves Pfizer's DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B - Business Wire
- 2 days ago - UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant - Reuters
- 2 days ago - Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study - Benzinga
- 2 days ago - Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial - CNBC
- 2 days ago - Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial - Reuters
- 2 days ago - Pfizer announces positive results from late-stage trial of Hemophilia A treatment - Market Watch
- 2 days ago - Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate - Business Wire